Molecular Imaging

In patients who had at least four cycles of 177Lu-PSMA-I&T for mCRPC, new research shows that a 10 percent or greater decrease in total kidney volume on CT at six months has a 90 percent AUC for predicting estimated glomerular filtration rates (eGFRs) of 30 percent or greater at one year.

The PET radiopharmaceutical SAR-bisPSMA has garnered three FDA fast track designations in a six-month period for use in the detection and management of prostate cancer.

18F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.

Reviewing current and emerging trends in imaging utilization and the impact of attrition rates and radiology residency positions on the field, researchers explore the future of radiology with two new provocative studies.

Catch up on the top radiology content of the past week.

Phase 2 studies of the BR55 ultrasound contrast agent reportedly demonstrated a 95 percent accuracy in showing the expression of vascular endothelial growth factor receptor 2 (VEGFR2) in bowel segments reflecting active inflammation in patients with Crohn’s disease.

Catch up on the most well-viewed video interviews from Diagnostic Imaging in January 2025.

Catch up on the top radiology content of the past week.

In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.

Previously approved for the detection of neuritic beta amyloid plaque, the PET agent (18F)florbetaben is currently being evaluated in a phase 3 multicenter trial for the diagnosis of cardiac amyloidosis.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

The appropriate use criteria (AUC) reflect updates to the 2013 AUC for amyloid PET and new criteria for tau PET in the diagnosis and monitoring of patients with mild cognitive impairment (MCI).

Catch up on the top radiology content of the past week.

Catch up on the most well-viewed video interviews from Diagnostic Imaging in 2024.

Touching on a variety of topics in radiology, here are the top five most well-viewed content from Diagnostic Imaging in 2024.

Catch up on the most well-viewed prostate imaging content from 2024.

Catch up on the most-well viewed radiology content in December 2024.

Catch up on the top AI-related news and research in radiology over the past month.

Catch up on the most well-read mammography articles from 2024.

Catch up on the top radiology content of the past week.

In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).

Catch up on the top radiology content of the past week.

Catch up on the most-well viewed radiology content in November 2024.

Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.

Catch up on the top radiology content of the past week.

In newly published guidelines, researchers discuss the utility of CT, MRI and PET/CT in the diagnosis, staging, treatment monitoring and follow-up imaging for peritoneal metastases in patients with ovarian or colorectal cancer.

Catch up on the top radiology content of the past week.

Designed for theranostic imaging applications, the AnyScan Trio SPECT/CT TheraMax scanner was recently unveiled at the annual meeting of the European Association of Nuclear Medicine (EANM).

Offering standardized assessment of amyloid plaque and insights on tau protein tangles, the newly clearly FDA features of Centiloid scoring and tau PET quantification with syngo.PET Cortical Analysis software may facilitate diagnosis of Alzheimer’s disease.